NORTH BRUNSWICK, N.J., June 27, 2023 /PRNewswire/ -- Ascendia Pharmaceuticals CEO Jim Huang, Ph.D. announces Ascendia's patented EmulSol® nanotechnology has been used to develop a novel nanoemulsion IV formulation for clopidogrel that has received Investigational New Drug (IND) approval from the Food & Drug Administration (FDA). Ascendia, a leading specialty CDMO, developed the formulation in partnership with AcuteBio, LLC.
Enforcement Report - Week of April 12, 2023
Enforcement Report - Week of March 8, 2023
Enforcement Report - Week of November 2, 2022
Enforcement Report - Week of September 8, 2021
Optimal antiplatelet monotherapy during the chronic maintenance period in patients who undergo coronary stenting is unknown. We aimed to compare head to head the efficacy and safety of aspirin and clopidogrel monotherapy in this population.
Polygen Pharms Generic Clopidogrel Bisulfate Receives Approval in US
International Laboratories Issues Voluntary Nationwide Recall of One (1) Lot of Clopidogrel Tablets USP, 75 mg Packaged in Bottles of 30 Tablets
Bristol-Myers Squibb (B-MS) and Sanofi filed a complaint this week in the US District Court for Hawaii to fight a lawsuit brought on by the state, which sought hundreds of millions in civil penalties for the companies’ failure to make certain statements about the cardiovascular drug Plavix (clopidogrel).
Mylan S.A.S` Clopidogrel/Acetylsalicylic acid Receives Approval in Europe